Synthetic Biologics, Inc.(NYSE Amex Equities : SYN)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||5.98%||12.76||0.7%||$891.97m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.63%||187.18||1.9%||$494.23m|
|GILD||Gilead Sciences, Inc.||-1.39%||66.28||1.0%||$473.61m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.07%||535.66||2.7%||$374.79m|
|ALXN||Alexion Pharmaceuticals, Inc.||-0.36%||179.33||2.0%||$336.10m|
|EXAS||EXACT Sciences Corp.||-1.42%||125.10||18.1%||$188.05m|
|IOVA||Iovance Biotherapeutics, Inc.||-1.46%||24.26||0.0%||$167.66m|
|TXG||10X Genomics, Inc.||-2.07%||194.67||0.0%||$167.62m|
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.